Events and Presentations
Alexion News
Click here to view more news about Alexion.
SOLIRIS® (eculizumab): The first and only medication approved specifically to treat PNH.
Click here to learn more...
Click here
|
IMPORTANT SAFETY INFORMATION WARNING: SERIOUS MENINGOCOCCAL INFECTION
SOLIRIS® increases the risk of meningococcal infections. Patients should be vaccinated with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS®. Revaccinate according to current medical guidelines for vaccine use. Patients should be monitored closely for early signs of meningococcal infections and evaluated immediately if infection is suspected, and treated with antibiotics if necessary. SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS. The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough. Please see important safety information (including boxed warning) as well as the complete prescribing information. |